Citations 1
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).
Wolff, Robert A. , Kindler, Hedy L. , Evans, Douglas B. , Misdraji, Joseph , Tamm, Eric P. , Sahani, Dushyant V., Moore, Malcolm J. , Newman, Elliot , Merchant, Nipun B. , Goff, Laura W. , Pisters, Peter W. T., Posner, Mitchell C. , (Alliance), ACOSOG, Wei, Alice C. , Ou, Fang‐Shu , Shi, Qian , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Deshpande, Vikram , Berlin, Jordan D. , (Alliance), ACOSOG
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4112-4112
